VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,976 | -89.5% | 428 | -86.4% | 0.00% | -100.0% |
| Q2 2023 | $66,337 | +72797.8% | 3,138 | -30.8% | 0.00% | -33.3% |
| Q1 2023 | $91 | +378.9% | 4,534 | +520.2% | 0.00% | +200.0% |
| Q4 2022 | $19 | -99.7% | 731 | +32.2% | 0.00% | – |
| Q3 2022 | $6,000 | -25.0% | 553 | -74.0% | 0.00% | – |
| Q2 2022 | $8,000 | +60.0% | 2,126 | +106.2% | 0.00% | – |
| Q1 2022 | $5,000 | +150.0% | 1,031 | +209.6% | 0.00% | – |
| Q4 2021 | $2,000 | -80.0% | 333 | -81.3% | 0.00% | – |
| Q3 2021 | $10,000 | +11.1% | 1,777 | +30.2% | 0.00% | – |
| Q2 2021 | $9,000 | +800.0% | 1,365 | +582.5% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 200 | -23.7% | 0.00% | – |
| Q2 2019 | $1,000 | -50.0% | 262 | -28.4% | 0.00% | – |
| Q1 2019 | $2,000 | -50.0% | 366 | -17.2% | 0.00% | – |
| Q4 2018 | $4,000 | +33.3% | 442 | +73.3% | 0.00% | – |
| Q3 2018 | $3,000 | 0.0% | 255 | 0.0% | 0.00% | – |
| Q2 2018 | $3,000 | -66.7% | 255 | -45.7% | 0.00% | -100.0% |
| Q1 2018 | $9,000 | +200.0% | 470 | +136.2% | 0.00% | – |
| Q3 2017 | $3,000 | – | 199 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,111,112 | $11,356,000 | 29.98% |
| Aisling Capital Management LP | 1,332,485 | $13,618,000 | 9.04% |
| Abingworth LLP | 2,457,500 | $25,091,000 | 8.58% |
| Fairmount Funds Management LLC | 2,678,982 | $27,379,000 | 4.81% |
| Vivo Capital, LLC | 4,249,918 | $43,434,000 | 4.80% |
| NEA Management Company, LLC | 5,584,753 | $57,076,000 | 2.85% |
| Octagon Capital Advisors LP | 1,324,868 | $13,540,000 | 2.34% |
| Samsara BioCapital, LLC | 938,890 | $9,595,000 | 2.24% |
| ACT CAPITAL MANAGEMENT, LLC | 143,500 | $1,467,000 | 2.02% |
| Frazier Life Sciences Management, L.P. | 2,099,541 | $21,457,000 | 1.65% |